Comparing new anticoagulants.

Link to article at PubMed

Related Articles

Comparing new anticoagulants.

South Med J. 2012 Dec;105(12):665-9

Authors: Wooten JM

Abstract

ABSTRACT: For years, the pharmaceutical industry has been trying to find a safe and effective drug to replace warfarin. Although warfarin is an effective anticoagulant, its pharmacology, adverse effects, and risk profiles dictate that patients taking this medication must be monitored judiciously. The US Food and Drug Administration has approved two drugs for commercial use, dabigatran and rivaroxaban, that will compete directly with warfarin for use in specific indications. Because of direct marketing to patients, physicians are being asked to comment on these new medications. This brief review illustrates the data available for the two new drugs when compared to warfarin for the specified indications. For some patients, these drugs may be highly beneficial and offer an excellent alternative to warfarin. For others, warfarin may still be the preferred drug.

PMID: 23211502 [PubMed - in process]

Leave a Reply

Your email address will not be published. Required fields are marked *